Xingcheng Yang

Xingcheng Yang

Auto-generated profile, based on publicly available information

Xingcheng Yang

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2024 in American Journal of Hematology
Verified
Journal Article
Open access
HQHu Qian
Hu Qian
XYXingcheng Yang
Xingcheng Yang
TZTingting Zhang
Tingting Zhang
PZPing Zou
Ping Zou
YZYicheng Zhang
Yicheng Zhang
JWJia Wei
Jia Wei
Chimeric antigen receptor (CAR) T‐cell therapy, an innovative immunotherapeutic against relapsed/refractory B‐cell lymphoma, faces challenges due to frequent viral infections. Despite this, a comprehensive review addressing risk assessment, surveillance, and treatment management is notably absent. This review elucidates immune response compromises during viral infections in CAR‐T recipients, collates susceptibility risk factors, and deliberates on preventive strategies. In the post‐pandemic era, marked by the Omicron variant, new and severe threats to CAR‐T therapy emerge, necessitating exploration of preventive and treatment measures for COVID‐19. Overall, the review provides recommendations for viral infection prophylaxis and management, enhancing CAR‐T product safety and recipient survival.

20 January 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
AZAnqi Zhang
Anqi Zhang
XYXingcheng Yang
Xingcheng Yang
YZYicheng Zhang
Yicheng Zhang
XYXiaoxuan Yu
Xiaoxuan Yu
伟穆伟 穆
伟 穆
JWJia Wei
Jia Wei
Myeloid malignancies include various types of cancers that arise from the abnormal development or proliferation of myeloid cells within the bone marrow. Chimeric antigen receptor (CAR) T cell treatments, which show great potential for B cell and plasma cell cancers, face major challenges when used for myeloid malignancies. CAR natural killer (NK) cell–based immunotherapy encounters several challenges in treating myeloid cancers, including (i) poor gene transfer efficiency and expansion platforms in vitro, (ii) limited proliferation and persistence in vivo, (iii) antigenic heterogeneity, and (iv) an immunosuppressive tumor microenvironment. Despite these hurdles, “off-the-shelf” CAR-NK treatments showed encouraging results, marked by enhanced proliferation, prolonged persistence, enhanced tumor infiltration, and improved adaptability. This review offers a summary of the biological traits and cellular sources of NK cells along with a discussion of contemporary CAR designs. Furthermore, it addresses the challenges observed in preclinical research and clinical trials related to CAR-NK cell therapy for myeloid cancers, suggesting enhancement strategies.

24 November 2023 in Frontiers in Bioscience-Landmark
Verified
Journal Article
Open access
PDF file
SHShaolong He
Shaolong He
JPJuan Peng
Juan Peng
XYXingcheng Yang
Xingcheng Yang
FMFankai Meng
Fankai Meng
LHLiang Huang
Liang Huang
JWJia Wei
Jia Wei
Background: Chimeric antigen receptor (CAR) T-cell therapy carries the risk of inducing severe and life-threatening toxicities such as cytokine release syndrome (CRS), neurotoxicity, and infection. Although CRS and infections have similar symptoms, their treatment strategies differ, and early diagnosis is very important. For CRS and infections, the fastest detection time currently takes more than 24 h, so a quick and simple method to identify a fever after CAR T-cell infusion is urgently needed. Methods: We enrolled 27 patients with recurrent fever treated with different types of CAR T-cells, including cluster of differentiation (CD) 7, CD19, CD22, and CD19-CD22 bicistronic CAR T-cells, and evaluated the infection events occurring in these patients. We detailed the morphology of CAR T-cells in peripheral blood smears (PBS) and reported the infection events, CAR transgene copy number, and inflammatory indicators within the first month after treatment. Results: Similar morphological characteristics were observed in the PBS of different CAR T-cells, namely, enlarged cell bodies, deep outside and shallow inside basophilic blue cytoplasm, and natural killer (NK) cell-like purplish red granules. There were ten infections in nine of the twenty-seven patients (33%). The percentage of atypical lymphocytes in PBS was significantly associated with CAR transgene copy number and absolute lymphocyte count in all patients. The atypical lymphocyte percentage was significantly higher in the non-infection group. Conclusions: In conclusion, the unique morphology of CAR T-cells in PBS can be used to evaluate CAR T-cell kinetics and provide reliable evidence for the rapid early identification of fever after CAR T-cell infusion. Clinical Trial Registrations: ChiCTR-OPN-16008526; ChiCTR-OPN-16009847; ChiCTR2000038641; NCT05618041; NCT05388695.

20 December 2024 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
JXJuan Xiao
Juan Xiao
XYXingcheng Yang
Xingcheng Yang
NWNanhai Wu
Nanhai Wu
SFShifen Fan
Shifen Fan
ZLZhouyang Liu
Zhouyang Liu
YSYuan Sun
Yuan Sun

27 October 2026 in Cancer Discovery
Verified
Journal Article
Open access
SWShuang Wei
Shuang Wei
JGJiaqi Guo
Jiaqi Guo
XBXueli Bai
Xueli Bai
LZLing Zhou
Ling Zhou
QMQi Mei
Qi Mei
JWJia Wei
Jia Wei
Mitigating on-target off-tumor toxicity remains a central challenge for chimeric antigen receptor (CAR) T-cell therapy for solid tumors. We developed a hypoxia-inducible CAR-T-cell product targeting carcinoembryonic antigen (CEA) that restricts CAR activation to hypoxic tumor niches via oxygen-dependent expression control. In this first-in-human, phase I trial enrolling heavily pretreated patients with relapsed stage IV non-small cell lung cancer (NSCLC), a single infusion of the investigational product achieved an objective response rate of 47% and a disease control rate of 87%, with a manageable safety profile. Exploratory analyses showed that clinical outcomes were associated with baseline factors. Deep single-cell profiling indicated that the clinical response was associated with the expansion of hypoxia-adapted, tumor-reactive-like CD8+ T cells alongside coordinated functional maturation of natural killer (NK) cells. Collectively, these data provide clinical proof-of-concept for hypoxia-inducible CAR design and inform the rational development of strategies leveraging tumor microenvironmental features in solid tumor cellular immunotherapy.